OBJECTIVES: • To better understand the natural history of weight change with androgen-deprivation therapy (ADT), we investigated the effect of ADT on body weight among men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. • Men undergoing ADT lose lean muscle but gain fat mass, contributing to an overall gain in weight. PATIENTS AND METHODS: • We identified 132 men in SEARCH who received ADT after radical prostatectomy. • 'Weight change' was defined as the difference in weight before starting ADT (6 months before ADT) and the on-ADT weight (between 6 and 18 months after starting ADT). • In a subanalysis, baseline characteristics of weight-gainers and -losers were analysed using univariate and multivariate analysis to test association with weight change. RESULTS: • In all, 92 men (70%) gained weight, and 40 (30%) either lost or maintained a stable weight. • On average, weight on ADT was 2.2 kg higher than the weight before ADT, with the mean change for weight-gainers and -losers being +4.2 kg and -2.4 kg, respectively. • This compared with no significant weight change in the year before starting ADT (paired t-test, change -0.7 kg, P= 0.19) or in the second year on ADT (paired t-test, change -0.5 kg, P= 0.46) for 84 men in whom these additional weight values were recorded. • There was no significant association between any of the features examined and weight change on univariate and multivariate analysis. CONCLUSION: • In this longitudinal study, ADT was accompanied by significant weight gain (+2.2 kg). This change occurred primarily in the first year of therapy, with men neither losing nor gaining additional weight thereafter.
OBJECTIVES: • To better understand the natural history of weight change with androgen-deprivation therapy (ADT), we investigated the effect of ADT on body weight among men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. • Men undergoing ADT lose lean muscle but gain fat mass, contributing to an overall gain in weight. PATIENTS AND METHODS: • We identified 132 men in SEARCH who received ADT after radical prostatectomy. • 'Weight change' was defined as the difference in weight before starting ADT (6 months before ADT) and the on-ADT weight (between 6 and 18 months after starting ADT). • In a subanalysis, baseline characteristics of weight-gainers and -losers were analysed using univariate and multivariate analysis to test association with weight change. RESULTS: • In all, 92 men (70%) gained weight, and 40 (30%) either lost or maintained a stable weight. • On average, weight on ADT was 2.2 kg higher than the weight before ADT, with the mean change for weight-gainers and -losers being +4.2 kg and -2.4 kg, respectively. • This compared with no significant weight change in the year before starting ADT (paired t-test, change -0.7 kg, P= 0.19) or in the second year on ADT (paired t-test, change -0.5 kg, P= 0.46) for 84 men in whom these additional weight values were recorded. • There was no significant association between any of the features examined and weight change on univariate and multivariate analysis. CONCLUSION: • In this longitudinal study, ADT was accompanied by significant weight gain (+2.2 kg). This change occurred primarily in the first year of therapy, with men neither losing nor gaining additional weight thereafter.
Authors: Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Shehzad Basaria; John Lieb; Alice M Tang; Theodore DeWeese; Michael Carducci; Mario Eisenberger; Adrian S Dobs Journal: Clin Endocrinol (Oxf) Date: 2002-06 Impact factor: 3.478
Authors: Tony Soeyonggo; Jennifer Locke; Maria Elizabeth Del Giudice; Shabbir Alibhai; Neil Eric Fleshner; Padraig Warde Journal: Can Urol Assoc J Date: 2014-03 Impact factor: 1.862
Authors: Emma H Allott; Lauren E Howard; Hai-Jun Song; Katharine N Sourbeer; Bridget F Koontz; Joseph K Salama; Stephen J Freedland Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-21 Impact factor: 4.254
Authors: Adriana C Vidal; Lauren E Howard; Amanda de Hoedt; Christopher J Kane; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2018-04-10 Impact factor: 5.588
Authors: Alyssa N Troeschel; Terryl J Hartman; Eric J Jacobs; Victoria L Stevens; Ted Gansler; W Dana Flanders; Lauren E McCullough; Ying Wang Journal: J Clin Oncol Date: 2020-04-06 Impact factor: 44.544
Authors: Kagan Griffin; Ilona Csizmadi; Lauren E Howard; Gina-Maria Pomann; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Martha K Terris; Jennifer Beebe-Dimmer; Stephen J Freedland Journal: Cancer Causes Control Date: 2019-01-30 Impact factor: 2.506